[Management of chronic hepatitis B: effective antiviral agents are available, but what now?].

For the treatment of chronic hepatitis B, tenofovir is able to maintain long-term viral suppression without the development of antiviral resistance. Long-term viral remission results in regression of fibrosis and even cirrhosis. With the availability of such effective antiviral agents, it has become even more important to identify patients with chronic hepatitis B, who are at risk for progression to cirrhosis and hepatocellular carcinoma. Nevertheless, the disadvantages of long-term treatment, including cost and safety, should be considered as well. In addition, treatment should only be provided in patients for whom a clear clinical benefit has been demonstrated.
AuthorsJurriën G P Reijnders
JournalNederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 157 Issue 16 Pg. A6146 ( 2013) ISSN: 1876-8784 [Electronic] Netherlands
Vernacular TitleAntivirale behandeling van chronische hepatitis B: er zijn effectieve middelen, maar hoe nu verder?
PMID23594875 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antiviral Agents
  • Antiviral Agents (economics, therapeutic use)
  • Carcinoma, Hepatocellular (prevention & control)
  • Cost-Benefit Analysis
  • Disease Progression
  • Drug Resistance, Viral
  • Hepatitis B, Chronic (drug therapy)
  • Humans
  • Liver Cirrhosis (prevention & control)
  • Liver Neoplasms (prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: